Asset profile

Aflibercept · Eylea

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved — Age-Related Macular Degeneration

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (4)
August 2026 (1)
Phase 2Age-Related Macular DegenerationActive not recruiting
Est. primary completion 2026-08-31 · NCT06116890 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (2)
Phase 3Age-Related Macular DegenerationNot yet recruiting
Est. primary completion 2026-09 · NCT06470373 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Age-Related Macular DegenerationNot yet recruiting
Est. primary completion 2026-09 · NCT05251636 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 3Age-Related Macular DegenerationActive not recruiting
Est. primary completion 2026-12-22 · NCT06856577 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (2)
May 2027 (1)
Phase 1/2Age-Related Macular DegenerationActive not recruiting
Est. primary completion 2027-05 · NCT05769153 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 3Age-Related Macular DegenerationRecruiting
Est. primary completion 2027-11-15 · NCT07482176 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
June 2028 (1)
Phase 2Age-Related Macular DegenerationRecruiting
Est. primary completion 2028-06-30 · NCT07205887 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)
Phase 3Age-Related Macular DegenerationRecruiting
Est. primary completion 2028-12 · NCT04663750 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
February 2029 (1)
Phase 2/3Age-Related Macular DegenerationNot yet recruiting
Est. primary completion 2029-02-01 · NCT07520318 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.